Advancing Immuno‑Oncology Breakthroughs & Reducing Toxicity Risks Through Next‑Generation Preclinical Models
- Discovering how strategic combination approaches can meaningfully elevate the therapeutic power of CD3 bispecifics, driving stronger, more durable T‑cell responses, improving tumor clearance, and overcoming resistance mechanisms that limit efficacy in current therapies
- Gaining insights into cutting‑edge preclinical methods designed to minimize cytokine‑driven toxicity and on‑target/off‑tumour effects
- Understanding how engineering innovations, conditional activation formats, and optimized dosing strategies can expand therapeutic windows and improve the safety profile of next‑generation immunotherapies